GHRP-2
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Key Takeaway
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus. It was developed as a second-generation GHRP with greater potency than GHRP-6, its predecessor, while producing somewhat less dramatic appetite stimulation. GHRP-2 occupies a middle ground in the GHRP family: more selective than GHRP-6, which triggers extreme hunger, but less selective than ipamorelin, which produces minimal cortisol or prolactin elevation.
Research in healthy adults and GH-deficient patients has documented robust GH pulses following GHRP-2 administration, typically peaking within 15 to 60 minutes of injection (PMID: 9467542). Because GHRP-2 also raises cortisol and prolactin, its side effect profile is broader than ipamorelin but narrower than GHRP-6 or hexarelin.
| Type | Growth Hormone |
| FDA Status | Research Only |
| Evidence Level | Moderate |
| Typical Dose | 100-300 mcg per injection |
| Frequency | 2-3 times daily, ideally on an empty stomach |
| Cycle Length | 8-12 weeks, followed by a 4-week break to maintain receptor sensitivity |
| Key Goals | muscle-growth, recovery, anti-aging |
How it works
GHRP-2 acts as a synthetic agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily in the hypothalamus and pituitary gland. Binding at GHS-R1a triggers a downstream signaling cascade involving phospholipase C activation and intracellular calcium mobilization, which stimulates somatotroph cells in the anterior pituitary to release stored growth hormone into circulation. GHRP-2 also acts at the hypothalamic level, stimulating growth hormone-releasing hormone (GHRH) release while suppressing somatostatin, the inhibitory hormone that blunts GH secretion. This dual hypothalamic action amplifies the pituitary GH response beyond what pituitary stimulation alone would produce (PMID: 9467542).
Because GHS-R1a is also expressed in the adrenal cortex and lactotroph cells of the pituitary, GHRP-2 administration produces measurable increases in cortisol and prolactin alongside GH. Clinical studies in healthy male subjects showed GHRP-2 raised cortisol levels significantly within 30 minutes, distinguishing it from ipamorelin, which produces negligible cortisol changes at therapeutic doses (PMID: 15265848). The cortisol elevation is dose-dependent and transient, typically returning to baseline within 2 to 3 hours. Prolactin elevation follows a similar time course. Both off-target hormonal effects become clinically relevant with high doses or very frequent injection schedules.
GHRP-2's appetite-stimulating effect is mediated through central ghrelin receptor activation in the arcuate nucleus of the hypothalamus, the region governing hunger signaling. While GHRP-2 does increase appetite compared to baseline, its appetite effects are substantially less pronounced than GHRP-6, making GHRP-2 more manageable for users who want GH stimulation without intense, persistent hunger. GH pulses following GHRP-2 injection typically peak at 15 to 30 minutes and return to baseline within 90 minutes, consistent with the pulsatile pattern of natural GH secretion.
Benefits
- Produces robust GH pulses documented in both healthy subjects and GH-deficient patients, with peak GH concentrations occurring 15 to 60 minutes post-injection at doses of 1 to 2 mcg/kg (PMID: 9467542)
- Stimulates GH release through a dual mechanism, activating pituitary somatotrophs directly while also suppressing somatostatin at the hypothalamic level, producing larger GH pulses than either pathway alone
- Moderate appetite stimulation that may support caloric surplus in hard-gaining individuals or those with appetite suppression from illness or aggressive dieting, without the overwhelming hunger associated with GHRP-6
- Supports body composition improvements through GH-mediated lipolysis (fat breakdown) and IGF-1 elevation, though direct body composition trials in healthy adults are limited compared to pharmaceutical GH studies
- Recovery enhancement through GH-driven protein synthesis and tissue repair signaling, with subjective reports of improved sleep quality common among research users, consistent with GH's role in slow-wave sleep regulation
- Synergistic GH amplification when combined with a GHRH analog such as CJC-1295 or modified GRF(1-29), with published data showing combination protocols produce substantially larger GH pulses than either peptide alone (PMID: 15265848)
- More selective than GHRP-6 for GH release relative to cortisol and prolactin elevation, making it a better-tolerated option for users who found GHRP-6 side effects difficult to manage
- Maintains pulsatile GH release pattern that more closely mimics natural physiology than continuous GH analog infusion, potentially reducing the risk of receptor downregulation with appropriate dosing intervals
Clinical comparisons
Among the synthetic GHRPs, GHRP-2 sits between GHRP-6 and ipamorelin in both potency and side effect burden. GHRP-6 produces more intense appetite stimulation and greater cortisol elevation than GHRP-2 but comparable raw GH output. Ipamorelin produces less cortisol and negligible prolactin elevation while still generating meaningful GH pulses, making it the better choice for users prioritizing selectivity.
Hexarelin surpasses GHRP-2 in peak GH output but desensitizes fastest and carries the heaviest cortisol and prolactin burden. MK-677 (ibutamoren), an oral ghrelin mimetic, produces sustained GH and IGF-1 elevation over 24 hours rather than discrete pulses, which eliminates injection burden but also eliminates pulsatility and produces persistent appetite stimulation throughout the day. GHRP-2 is the preferred GHRP for users who want stronger GH stimulation than ipamorelin provides but find GHRP-6's appetite effects unmanageable.
Side effects
- Cortisol elevation: GHRP-2 raises cortisol transiently after each injection, with peak increases occurring at approximately 30 minutes and returning to baseline within 2 to 3 hours. Frequent dosing (more than 3 times daily) may sustain cortisol elevation and impair recovery or sleep quality (PMID: 15265848)
- Prolactin elevation: Measurable prolactin increases follow each injection through GHS-R1a activation in pituitary lactotrophs. Sustained prolactin elevation with high-dose or high-frequency protocols may cause gynecomastia risk in men or menstrual irregularities in women
- Appetite stimulation: Noticeable hunger typically begins within 20 to 30 minutes of injection and lasts 1 to 2 hours. Less severe than GHRP-6 but more pronounced than ipamorelin. Timing injections before planned meals can convert this side effect into a practical benefit
- Water retention: GH elevation drives fluid retention through aldosterone and antidiuretic hormone interactions. Transient bloating and mild edema are common in the first few weeks of use and typically resolve as the body adapts to elevated GH signaling
- Injection site reactions: Localized redness, mild swelling, or itching at the injection site occur with subcutaneous administration, particularly when injecting the same site repeatedly. Rotating injection sites minimizes this effect
- Tingling or numbness: Some research subjects report transient peripheral tingling, particularly in the hands, consistent with GH-mediated fluid shifts and effects on peripheral nerves. This effect is typically mild and resolves within hours
- Potential for receptor desensitization with very high-dose or very high-frequency protocols, though GHRP-2 desensitizes more slowly than hexarelin. Standard 2 to 3 times daily protocols at 100 to 200 mcg appear to preserve receptor sensitivity across typical cycle lengths
Dosing protocol
Typical Dose
100-300 mcg per injection
Frequency
2-3 times daily, ideally on an empty stomach
Cycle Length
8-12 weeks, followed by a 4-week break to maintain receptor sensitivity
Inject subcutaneously into the abdomen or another low-fat tissue site. Fasting before injection is important: food (especially carbohydrates and fat) blunts GH release by elevating insulin and somatostatin. Aim to inject at least 2 hours after a meal and wait 20 to 30 minutes before eating afterward. The three most common timing windows are morning (upon waking, fasted), pre-workout (45 to 60 minutes before training), and pre-sleep (2 hours after last meal). The pre-sleep dose aligns with the largest natural GH pulse, which occurs during slow-wave sleep. GHRP-2 is most effective when stacked with a GHRH analog such as CJC-1295 or modified GRF(1-29), which primes the pituitary for maximal GH release. This combination produces substantially larger GH pulses than either peptide used alone. Users aiming to minimize cortisol and prolactin side effects while still achieving GH stimulation may prefer ipamorelin, which is more selective. Users who accept broader side effects in exchange for the strongest possible GH pulse may prefer hexarelin.
Deeper on GHRP-2
Full breakdowns of every part of the GHRP-2 research base.
What you will need
Basic supplies for reconstitution and subcutaneous injection.
This page contains affiliate links. Learn more
Bacteriostatic Water (30mL)
$8-15Required for reconstituting lyophilized peptides. 30mL is standard.
Insulin Syringes (1mL, 29ga)
$12-20 (100ct)1mL insulin syringes with 29-gauge needles for subcutaneous injection.
Alcohol Prep Pads
$5-10 (200ct)Sterile 70% isopropyl alcohol wipes for injection site prep.
Sharps Container
$8-15FDA-cleared sharps disposal container for used needles.
Get the GHRP-2 cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Key research
Comparison of growth hormone (GH)-releasing peptides: stimulation of GH release from perifused rat anterior pituitaries by GHRP-1, GHRP-2, GHRP-6, hexarelin, and MK-0677
Endocrinology (1997) — PubMed
Direct head-to-head comparison of GHRPs demonstrated GHRP-2 produces potent GH release from pituitary tissue, with its relative potency and selectivity profile positioned between GHRP-6 and ipamorelin in the GHRP family.
Growth hormone (GH)-releasing peptide-2 administration elevates GH and insulin-like growth factor-I concentrations and enhances nitrogen retention in normal subjects
Journal of Clinical Endocrinology and Metabolism (2004) — PubMed
In healthy adult subjects, GHRP-2 administration significantly increased GH and IGF-1 concentrations while also elevating cortisol and prolactin, establishing the dual GH-stimulating and cortisol-raising profile that distinguishes GHRP-2 from more selective GHRPs.
Mechanism of action of growth hormone-releasing peptides
Endocrine Reviews (1999) — PubMed
Comprehensive mechanistic review confirming GHRP-2 acts through the GHS-R1a receptor with both direct pituitary effects and hypothalamic GHRH release plus somatostatin suppression, explaining the amplified GH response observed with GHRH co-administration.
Real-world data
Research users commonly report GHRP-2 as a step up from ipamorelin for GH stimulation, noting more noticeable body composition changes over 8 to 12 week cycles when stacked with CJC-1295. The cortisol elevation is generally described as less disruptive than hexarelin but more noticeable than ipamorelin, particularly when dosing 3 times daily. Community consensus among experienced users is to use GHRP-2 on 2 times daily schedules (morning and pre-sleep) rather than 3 times daily to limit cumulative cortisol exposure.
Appetite effects are described as manageable and predictable, peaking around 20 to 30 minutes post-injection and fading within 90 minutes. Sleep quality improvements are frequently noted with the pre-sleep dose, consistent with GH's known role in slow-wave sleep enhancement.
Get the GHRP-2 cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Frequently asked questions
How does GHRP-2 compare to ipamorelin?
GHRP-2 produces stronger GH pulses than ipamorelin but with more side effects, specifically measurable cortisol and prolactin elevation. Ipamorelin is considered the most selective GHRP, meaning it stimulates GH release with minimal impact on other hormones. GHRP-2 is a reasonable step up for users who feel ipamorelin's GH effects are insufficient, but ipamorelin remains the first choice when minimizing cortisol is a priority.
Does GHRP-2 cause hunger like GHRP-6 does?
GHRP-2 does stimulate appetite, but considerably less than GHRP-6. Most users describe a moderate hunger signal beginning about 20 to 30 minutes after injection, lasting roughly 1 to 2 hours. Timing injections before planned meals can turn this into a practical benefit rather than a problem. GHRP-6's hunger effect is substantially more intense and harder to manage.
Can GHRP-2 be used without a GHRH analog?
Yes, GHRP-2 produces GH pulses as a standalone peptide. However, combining it with a GHRH analog such as CJC-1295 or modified GRF(1-29) produces substantially larger GH responses than either peptide alone, because the GHRH analog primes the pituitary while GHRP-2 simultaneously suppresses somatostatin inhibition. Most research protocols use both peptides together for this synergistic effect.
Will GHRP-2 raise my cortisol levels significantly?
GHRP-2 does produce a transient cortisol increase with each injection, typically peaking around 30 minutes and resolving within 2 to 3 hours. For most users on standard protocols (100 to 200 mcg twice daily), this transient elevation does not meaningfully disrupt recovery or body composition. Users who are particularly cortisol-sensitive or who are managing adrenal fatigue may prefer ipamorelin, which produces negligible cortisol changes.
How long before GHRP-2 starts working and what results can be expected?
GH pulses begin within 15 minutes of injection and are measurable in blood within 30 to 60 minutes. Subjective effects like improved sleep quality and recovery often appear within the first 2 to 4 weeks of consistent use. Body composition changes, including reduced body fat and increased lean mass, typically become noticeable over 8 to 12 week cycles, with results depending heavily on diet, training, and whether a GHRH analog is used alongside GHRP-2.
Compare GHRP-2
Related peptides
Looking for weight loss peptides? See our complete guide to the best peptides for weight loss or compare semaglutide vs tirzepatide .
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.